PCSK9 Inhibition Following Myocardial Infarction: A Right Time to Act

Can J Cardiol. 2022 Oct;38(10):1550-1552. doi: 10.1016/j.cjca.2022.06.013. Epub 2022 Jun 23.

Authors

Alexander A Leung¹, Todd J Anderson²

Affiliations

¹ Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada. Electronic address: [email protected].
² Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada; Department of Cardiac Sciences, Cumming School of Medicine, Calgary, Alberta, Canada.

PMID: 35753630
DOI: 10.1016/j.cjca.2022.06.013

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anticholesteremic Agents*
Cholesterol, LDL
Humans
Myocardial Infarction*
Proprotein Convertase 9

Substances

Anticholesteremic Agents
Cholesterol, LDL
PCSK9 protein, human
Proprotein Convertase 9